Do Not Miss this Educational Event!

The fourteenth annual North American Education Forum on Lymphoma, the most comprehensive lymphoma-specific educational conference on the continent, will be held this year from October 23 through October 25 in Brooklyn, New York. The goal of the 2 ½ day program is to provide information about treatment options for the various subtypes of lymphoma, patient support issues, and the latest in lymphoma research to people with lymphoma and their loved ones.

In addition, forum attendees have the opportunity to hear presentations and have specific questions answered by expert speaking faculty comprised of lymphoma specialists and patient support experts from around the world.

Program highlights include:

  • What is Lymphoma? A Pathologist's Perspective - Randy Gascoyne, MD, British Columbia Cancer Agency
  • Breakout Sessions: Disease-Specific Biology and Treatment Options
  • PET Scans: Uses and Abuses - Morton Coleman, MD, Center for Lymphoma and Myeloma, Weill Cornell Medical College, The New York Presbyterian Hospital
  • Immunotherapy - John Leonard, MD, Weill Cornell Medical College, The New York Presbyterian Hospital
  • Cardiac Toxicity - Richard Steingart, MD, Memorial Sloan-Kettering Cancer Center

Lymphoma survivors and care partners also will have the opportunity to interact with others dealing with the same type of lymphoma throughout the forum. For more information, contact the Lymphoma Research Foundation at (800) 500-9976.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap